Stem cells are the foundation from which all other cells with specialized functions are generated. Stem cells are primarily found in the bone marrow, where they are produced, but can be induced to migrate into the peripheral blood circulation through a process known as mobilization.
HemaCare has just announced the publication of their latest article in the popular stem cell industry periodical BioInformant.  The article focuses on the need for healthy donor starting material to keep up with growing demands in the cell and gene therapy industry.
HemaCare Corporation’s new global headquarters is officially open for business! The company started 2019 in a brand new 40,000 square foot space in a newly modernized 44-acre corporate campus located in the heart of the San Fernando Valley at Northridge. The design and construction of the cutting-edge facility provide a spacious workspace that promotes the well-being of its occupants, while significantly expanding the company’s on-site capabilities.
Cell therapy research publication RegMedNet has just posted HemaCare’s latest article on how to use apheresis and cell collection techniques to optimize starting material quality. 
An Expansive Donor Network Helps Guarantee Consistent Quality
Apheresis donor material is intrinsically variable, yet a successful cell therapy product must have consistent efficacy across a wide range of patients. How do we reconcile these realities? As a large-scale apheresis supplier, HemaCare understands that quality raw materials are a matter of careful planning and expertise. Inter-donor variability can impact critical parameters including cell collection volume, cell subtype composition and cell proliferation potential.  Each of these parameters impact apheresis unit potency, and can impact resource use and manufacturing efficiency.
Last week, HemaCare published an article in Technology Networks discussing how optimal apheresis and collection methods give cell therapies a leading edge1
Cell therapy is a unique field because the “products” are derived from living human cells and where each donor is different, variability is inevitable. Quality precursor material gives cell therapy products their best start. Variable or low-quality starting material introduces a need for complex separation strategies or repeated manufacturing runs, leading to higher costs and resource requirements.1 To ensure the process utilizes the right resources, scientists must adopt optimal apheresis instrumentation and collection methods as one of the most important steps.